Altimmune Stock Price, News & Analysis

Altimmune, Inc. (Nasdaq: ALT) will report its Q3 2022 financial results on November 10, 2022, followed by a management conference call at 8:30 am ET. The discussion will focus on financial performance and business updates. Live streaming of the call will be available on the company's Investor Relations website. Altimmune specializes in peptide-based therapeutics for obesity and liver diseases, with its lead candidate being pemvidutide, aimed at treating obesity and non-alcoholic steatohepatitis (NASH).

Altimmune, Inc. (Nasdaq: ALT) announced its upcoming scientific presentations at two conferences in November 2022. The first presentation, at the American Heart Association Scientific Sessions on November 5, will focus on the effects of Pemvidutide (ALT-801) on lipid mediators. The second, at the American Association for the Study of Liver Disease on November 7, will present results from a Phase 1b trial evaluating a dual receptor agonist's impact on liver fat reduction in patients with non-alcoholic fatty liver disease. Presentation materials will be accessible on Altimmune's website.

Altimmune, Inc. (Nasdaq: ALT) announced the successful completion of patient dosing for its Phase 2 MOMENTUM trial, evaluating the efficacy and safety of pemvidutide, a dual receptor agonist for obesity and NASH. This multicenter trial involves 320 subjects randomized to receive various doses of pemvidutide or placebo over 48 weeks, focusing on weight change and metabolic profiles. The trial's 24-week interim analysis is anticipated in Q1 2023, marking a significant milestone in pemvidutide's development.

Altimmune, Inc. (ALT) announced positive results from a 12-week Phase 1b study of pemvidutide for non-alcoholic fatty liver disease (NAFLD). All dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved primary endpoints, with a 68.5% relative reduction in liver fat at the 1.8 mg dose. Subjects without diabetes saw a mean weight loss of 4.9% (placebo-adjusted 4.7%). The treatment was well-tolerated, mainly with mild gastrointestinal events, and no serious adverse events were reported. Next steps include data from a 24-week NAFLD trial and interim results from the MOMENTUM obesity trial.

Altimmune, Inc. (Nasdaq: ALT) reported its financial results for the second quarter of 2022, with a net loss of $20.1 million or $0.42 per share, an improvement from a net loss of $24.8 million in Q2 2021. The company reported minimal revenue due to the discontinuation of T-COVID and NasoShield programs. Altimmune is advancing its pemvidutide clinical trials, with topline data from a 12-week Phase 1b trial in subjects with obesity/overweight and non-alcoholic fatty liver disease (NAFLD) expected in mid-September 2022.

Research and development expenses increased to $16 million, primarily due to pemvidutide development.

Altimmune, Inc. (Nasdaq: ALT) will announce its second quarter 2022 financial results on August 11, 2022, followed by a conference call at 8:30 am E.T. to discuss these results and provide a business update. The call will be accessible via webcast on Altimmune's Investor Relations website. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide, targeting obesity and NASH. Altimmune is also advancing its HepTcell™ immunotherapeutic for chronic hepatitis B.

Altimmune presented the results of its Phase 1 clinical trial for pemvidutide at the 2022 International Liver Congress, focusing on obesity and NASH treatment. The presentation, titled "Pemvidutide (ALT-801), a novel GLP-1/Glucagon Dual Receptor Agonist, Achieves Rapid and Potent Reductions in Body Weight and Liver Fat", was delivered by Dr. Stephen A. Harrison on June 25, 2022. The study displayed significant findings, earning a spot in the congress's Best of International Liver Congress. Additionally, Dr. Scott Harris will discuss study findings at a press conference on June 24, 2022.

Altimmune, Inc. (Nasdaq: ALT) announced its participation in two upcoming investor conferences in June 2022. The events include the Jefferies 2022 Global Healthcare Conference on June 10 at 10:00 am ET and the JMP Securities Life Sciences Conference on June 16 at 9:00 am ET, both held in New York. Interested investors can access the webcast via the company’s website. Altimmune develops novel therapeutics for obesity and liver diseases.

Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Samuel Klein will present at the 82^nd American Diabetes Association Scientific Sessions from June 3-7, 2022, in New Orleans, LA. He will discuss the results of a Phase 1 clinical trial for pemvidutide, a dual receptor agonist targeting obesity and NASH. The presentation is scheduled for June 6, 2022, at 4:30 pm CDT, highlighting pemvidutide's potential for significant weight loss without dose adjustments. Altimmune is committed to developing innovative peptide-based therapies for metabolic and liver diseases.